表紙
市場調查報告書
商品編碼
1018773

Hedgehog通路抑制劑的全球市場 (2021年∼2028年)

Global Hedgehog pathway inhibitors Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球在癌症患病率上升、遺傳因素、新產品發布、對無痛或微創治療的需求增加以及對現有療法的抗拒感的增加等要素下,Hedgehog通路抑制劑今後也將持續擴大。

本報告提供全球Hedgehog通路抑制劑的市場相關分析,提供市場規模趨勢預測,及各產品種類·各通路類型·各用途·各給藥途徑·各流通管道·各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業的簡介等相關調查。

目錄

第1章 全球Hedgehog通路抑制劑市場:分析方法·範圍

第2章 全球Hedgehog通路抑制劑市場:市場定義和概要

第3章 全球Hedgehog通路抑制劑市場:摘要整理

第4章 全球Hedgehog通路抑制劑市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球Hedgehog通路抑制劑市場:產業分析

  • 波特的五力分析
  • PEST分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球Hedgehog通路抑制劑市場:新型冠狀病毒感染疾病 (COVID-19)的分析

  • COVID-19對市場的影響分析
    • "COVID-19前" /過去的市場方案
    • "COVID-19中" /目前市場方案
    • "COVID-19後" /未來市場方案
  • COVID-19疫情中的價格趨勢
  • 需求與供給的變動階段
  • 政府在COVID-19感染擴大下的市場相關措施
  • 各製造公司的策略展開情形
  • 結論

第7章 全球Hedgehog通路抑制劑市場:各產品種類

  • 簡介
    • 市場規模的分析與與前一年同期相比成長率 (YoY):各產品種類
    • 市場向心力指數:各產品種類
  • Vismodegib
    • 簡介
    • 市場規模 (以金額為準,2018年∼2028年)·與前一年同期相比成長率 (YoY) (2020年∼2028年)
  • Glasdegib
  • Sonidegib
  • Itraconazole
  • Oxysterol
  • Saridegib

第8章 全球Hedgehog通路抑制劑市場:各通路類型

  • 簡介
  • 標準的Hedgehog信號傳達
  • 非標準的Hedgehog信號傳達
    • 平衡化依存的·非標準
    • 平衡化非依存的·非標準

第9章 全球Hedgehog通路抑制劑市場:各用途

  • 簡介
  • 基底細胞癌症
  • 急性骨髓性白血病
  • 髓母細胞瘤
  • Gorlin症候群
  • 其他

第10章 全球Hedgehog通路抑制劑市場:各給藥途徑

  • 簡介
  • 口服
  • 局部給藥

第11章 全球Hedgehog通路抑制劑市場:各流通管道

  • 簡介
  • 零售藥局
  • 醫院藥局
  • 線上藥局

第12章 全球Hedgehog通路抑制劑市場:各地區

  • 簡介
    • 市場規模 (以金額為準,2018年∼2028年)·與前一年同期相比成長率 (YoY) (2020年∼2028年):各地區
    • 市場向心力指數:各地區
  • 北美
    • 簡介
    • 域內市場固有趨勢
    • 市場規模·與前一年同期相比成長率 (YoY):各產品種類
    • 市場規模·與前一年同期相比成長率 (YoY):各通路類型
    • 市場規模·與前一年同期相比成長率 (YoY):各用途
    • 市場規模·與前一年同期相比成長率 (YoY):各給藥途徑
    • 市場規模·與前一年同期相比成長率 (YoY):各流通管道
    • 市場規模·與前一年同期相比成長率 (YoY):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第13章 全球Hedgehog通路抑制劑市場:競爭情形

  • 主要趨勢與策略
  • 企業佔有率分析
  • 產品的互相比較
  • 值得注意的企業
  • 有顛覆性技術的企業
  • Start-Ups企業

第14章 全球Hedgehog通路抑制劑市場:企業簡介

  • Sun Pharmaceutical Industries Limited
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 主要的財務指標
  • Pfizer Inc
  • F. Hoffmann-La Roche AG
  • Infinity Pharmaceuticals
  • Max Biopharma Inc
  • PellePharm Inc
  • Takeda Pharmaceutical Company Ltd
  • Mayne Pharma Group Limited
  • Bristol-Myers Squibb Company
  • Novartis

第15章 關於DataM Intelligence

目錄
Product Code: DMPH3563

Market Overview

The global hedgehog pathway inhibitors market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Hedgehog pathway inhibitors are relatively a new class of therapeutic agents that target the proteins involved in the regulation of the hedgehog pathway.

Market Dynamics

The hedgehog pathway inhibitors market growth is driven by the rising prevalence of cancer, hereditary factors, new product launches, rising demand for painless or minimally invasive treatment, and increased resistance to existing therapies.

The rising prevalence of cancer, is expected to drive the growth in the forecast period

The rising prevalence of cancer is boosting the Hedgehog pathway inhibitors market. For instance, according to the American Cancer Society, approximately 1,735,350 new cancer cases were registered for 2018 in the US. Nearly 9,500 people in the US are a target of skin cancer or Basal Cell Carcinoma. Estimation says that non-melanoma carcinoma, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million globally per year. According to the American Brain Tumor Association, approximately 25% of patients in the US are suffering from medulloblastoma due to the uncontrolled Sonic Hedgehog (SHH) pathway. Individuals with medulloblastoma showed a high cholesterol level when the combination of statin (simvastatin) and Hedgehog pathway inhibitor (vismodegib) was administered to the cohort. The combination therapeutics produces synergistic activity of the inhibitors.

The rise in the risk factors associated with basal cell carcinoma (BCC) and acute myeloid leukemia (AML), is expected to drive the growth in the forecast period

The rise in the risk factors associated with basal cell carcinoma (BCC) and acute myeloid leukemia (AML) is projected to fuel the global hedgehog pathway inhibitors market. The risk factors associated with developing basal cell carcinoma and acute myeloid leukemia include chronic infections, history of skin cancer, exposure to certain chemicals, skin inflammations, smoking, and exposure to UV rays. These risk factors raise the prevalence and incidence of basal cell carcinoma and acute myeloid leukemia. This, in turn, is anticipated to boost the growth of the global hedgehog pathway inhibitors market during the forecast period.

Side effects associated with hedgehog pathway inhibitors is likely to hamper the market growth

The most frequently encountered side effects were muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, anorexia, and diarrhea are likely to hamper the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has led to the halt of several industrial processes causing unprecedented economic loss. However, pharmaceutical companies are thriving in these difficult times owing to the increasing demand for medication drugs across the globe. Likewise, the demand for these hedgehog pathway inhibitors is experiencing considerable growth as major pharmaceutical companies focus on R&D activities to develop new drugs and cater to the demand for OTC drugs across several stores and high prevalence of chronic target diseases across the globe. The market is, therefore, expected to showcase positive growth during the forecast period.

Segment Analysis

The basal cell carcinoma segment is expected to hold largest share in this market segment

Basal cell carcinoma (BCC) is the most common human cancer detected in Western populations and poses significant health expenditure. For instance, according to the American Cancer Society (ACS), an estimated 5.4 million people are diagnosed with squamous and basal cell skin cancer globally each year. Of these, 3.3 million people suffer from squamous cell skin cancer, and about 80% of the population suffers from basal cell carcinoma.

The vismodegib segment is expected to hold largest share in this market segment

Vismodegib is a drug for the treatment of basal-cell carcinoma. The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration approval which Genentech Inc discovered under a collaboration with Curis Inc. Vismodegib inhibits the Hedgehog (Hh) pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.

The smoothened non-canonical pathway type of hedgehog inhibitors segment is expected to hold largest share in this market segment

Most basal cell carcinoma BCCs arise from the loss of patched homologue 1 (PTCH1) inhibition of the Smoothened (SMO) homologue. Smoothened is a protein that in humans is encoded by the SMO gene. Smoothened is a Class Frizzled (Class F) G protein-coupled receptor that is a component of the hedgehog signaling pathway and is conserved from flies to humans. It is the molecular target of the natural teratogen cyclopamine.

The oral route segment is expected to hold largest share in this market segment

Oral route for administration segment dominates the market due to the ease of application and efficient dose delivery to achieve desirable results, and oral drugs require no special skills and can easily carry around are some of the factors responsible for the market growth. For instance, In December 2018, Glasdegib, the first hedgehog pathway inhibitor drug, was approved for the treatment of acute myeloid leukemia (AML) patients. The drug was approved by the Food and Drug Administration (FDA) as once-daily oral medicine to be used in combination with low-dose cytarabine. Glasdegib is sold under the brand name Daurismo.

The retail pharmacies segment is expected to hold largest share in this market segment

The retail Pharmacies segment is expected to dominate during the forecast period. Hedgehog pathway inhibitors medications are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost hedgehog pathway inhibitors market growth.

Geographical Analysis

North America region holds the largest market share of global hedgehog pathway inhibitors market

North America served to dominate the global market during the forecast period. High prevalence of basal cell carcinoma & acute myeloid leukemia and new product approvals are anticipated to drive the hedgehog pathway inhibitors market in the region during the forecast period. according to the American Cancer Society (ACS), an estimated 5.4 million people are diagnosed with squamous and basal cell skin cancer globally each year. For instance, Pellepharm has introduced Saridegib (Patidegib), a hedgehog pathway inhibitor. It is used as a topical treatment measure for patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs).

Competitive Landscape

The global hedgehog pathway inhibitors market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Pfizer Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Infinity Pharmaceuticals, Max Biopharma Inc, PellePharm Inc., Takeda Pharmaceutical Company Ltd, Mayne Pharma Group Limited, and Bristol-Myers Squibb Company, Novartis. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Mayne Pharma Group Limited took control of SUBA-itraconazole BCCNS program from HedgePath Pharmaceuticals, Inc.

Hedgehog pathway inhibitors Market Key Companies to Watch

Sun Pharmaceutical Industries Limited

Company Overview: Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company founded in 1983, headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients primarily in India and the United States. Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion.

Product Portfolio: The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anti-cancers, steroids, peptides, sex hormones, and controlled substances.

Key Developments: In 2016, Sun Pharmaceutical Industries Ltd. acquired Novartis pipeline product Odomzo (Sonidegib).

Why Purchase the Report?

  • Visualize the composition of the hedgehog pathway inhibitors market segmentation by product type, route of administration, application, pathway type and region highlighting the key commercial assets and players.
  • Identify commercial opportunities hedgehog pathway inhibitors market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of hedgehog pathway inhibitors market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global hedgehog pathway inhibitors market report would provide an access to an approx. 77 market data table, 75 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Hedgehog pathway inhibitors Market - By Product Type

  • Glasdegib
  • Vismodegib
  • Sonidegib
  • Itraconazole
  • Oxysterol
  • Saridegib

Global Hedgehog pathway inhibitors Market - By Pathway Type

  • Canonical Hedgehog Signaling
  • Non-Canonical Hedgehog Signaling

Smoothened dependent non-Canonical

Smoothened independent non-Canonical

Global Hedgehog pathway inhibitors Market - By Route of Administration

  • Oral
  • Topical

Global Hedgehog pathway inhibitors Market - By Application

  • Basal Cell Carcinoma
  • Acute Myeloid Leukemia
  • Medulloblastoma
  • Gorlin Syndrome
  • Others

Global Hedgehog Pathway Inhibitors Market - By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Global Hedgehog pathway inhibitors Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Hedgehog pathway inhibitors Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Hedgehog pathway inhibitors Market - Market Definition and Overview

3. Global Hedgehog pathway inhibitors Market - Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Pathway Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Application
  • 3.5. Market Snippet by Distribution Channel
  • 3.6. Market Snippet by Region

4. Global Hedgehog pathway inhibitors Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing scientific advancements in the treatment for infantile spasm
      • 4.1.1.2. Rising prevalence of infantile spasms
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Hedgehog pathway inhibitors Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Hedgehog pathway inhibitors Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Hedgehog pathway inhibitors Market - By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Vismodegib*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Glasdegib
  • 7.4. Sonidegib
  • 7.5. Itraconazole
  • 7.6. Oxysterol
  • 7.7. Saridegib

8. Global Hedgehog pathway inhibitors Market - By Pathway Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathway Type
    • 8.1.2. Market Attractiveness Index, By Pathway Type
  • 8.2. Canonical Hedgehog Signaling*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Non-Canonical Hedgehog Signaling
    • 8.3.1. Smoothened dependent non-Canonical
    • 8.3.2. Smoothened independent non-Canonical

9. Global Hedgehog pathway inhibitors Market - By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Basal Cell Carcinoma*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Acute Myeloid Leukemia
  • 9.4. Medulloblastoma
  • 9.5. Gorlin Syndrome
  • 9.6. Others

10. Global Hedgehog pathway inhibitors Market - By Route of Administration

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 10.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 10.2. Oral*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Topical

11. Global Hedgehog pathway inhibitors Market - By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel Segment
    • 11.1.2. Market Attractiveness Index, By Distribution channel Segment
  • 11.2. Retail Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 11.3. Hospital Pharmacies
  • 11.4. Online Pharmacies

12. Global Hedgehog pathway inhibitors Market - By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathway Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathway Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathway Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathway Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathway Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Type
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Global Hedgehog pathway inhibitors Market - Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. Key Companies to Watch
  • 13.5. Company with disruptive technology
  • 13.6. Start Up Companies

14. Global Hedgehog pathway inhibitors Market- Company Profiles

  • 14.1. Sun Pharmaceutical Industries Limited*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Pfizer Inc
  • 14.3. F. Hoffmann-La Roche AG
  • 14.4. Infinity Pharmaceuticals
  • 14.5. Max Biopharma Inc
  • 14.6. PellePharm Inc
  • 14.7. Takeda Pharmaceutical Company Ltd
  • 14.8. Mayne Pharma Group Limited
  • 14.9. Bristol-Myers Squibb Company
  • 14.10. Novartis

LIST NOT EXHAUSTIVE

15. Global Hedgehog pathway inhibitors Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us